2002/29/EC: Commission Decision of 8 January 2002 on financial assistance from the Community for storage in France, Italy and the United Kingdom of antigens for production of foot-and-mouth disease vaccines (notified under document number C(2001) 4736)
Date: 2002-01-08
Institutions: European Commission
Subjects: France, Italy, United Kingdom, financial aid, foot-and-mouth disease, vaccine

16.1.2002

EN

Official Journal of the European Communities

L 13/25

II

(Acts whose publication is not obligatory)

COMMISSION

COMMISSION DECISION

of 8 January 2002

on financial assistance from the Community for storage in France, Italy and the United Kingdom of
antigens for production of foot-and-mouth disease vaccines

(notified under document number C(2001) 4736)

(2002/29/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European
Community,

Having regard to Council Decision 90/424/EEC of 26 June
1990 on expenditure in the veterinary field (1), as last amended
by Decision 2001/572/EC (2), and in particular Article 14
thereof,

Whereas:

(1)

(2)

(3)

(4)

By virtue of Council Decision 91/666/EEC of 11
December 1991 establishing Community reserves of
foot-and-mouth disease vaccines (3), as last amended by
Commission Decision 2001/181/EC (4), establishment of
antigen banks is part of the Community's action to
create Community reserves of foot-and-mouth disease
vaccines.

Article 3 of that Decision designates the ‘Laboratoire de
pathologie bovine du Centre national d'études vétéri-
naires et alimentaires’ at Lyon in France, which is now
part of the ‘Agence Française de Sécurité Sanitaire des
Aliments (ASSA)’, and the ‘Istituto Zooprofilattico Speri-
mentale die Brescia’
in Italy, as the antigen banks
holding Community reserves, and provides for a proce-
dure to designate other establishments as antigen bank
by Commission Decision.

Article 1 of Commission Decision 2000/111/EC (5)
further designates Merial SAS as the antigen bank
holding Community reserves.

The functions and duties of these antigen banks are
specified in Article 4 of Decision 91/666/EEC and
Community assistance must be conditional on accom-
plishment of these.

(1) OJ L 224, 18.8.1990, p. 19.
(2) OJ L 203, 28.7.2001, p. 16.
(3) OJ L 368, 31.12.1991, p. 21.
(4) OJ L 66, 8.3.2001, p. 39.
(5) OJ L 33, 8.2.2000, p. 19.

(5)

(6)

(7)

(8)

(9)

Community financial assistance should be granted to the
banks providing services to the Community to enable
them to carry out during 2002 the said functions and
duties.

For budgetary reasons the Community assistance should
be granted for a period of one year.

According to Article 3(2) of Council Regulation (EC) No
1258/1999 of 17 May 1999 on the financing of the
common agricultural policy (6), programmes for
the
eradication of animal diseases shall be financed under
the Guarantee Section of
financial
control purposes Articles 8 and 9 of this Regulation
apply.

the EAGGF;

for

The financial contribution of the Community shall be
granted to Member States provided that the authorities
supply all the necessary information within the time
limits set.

The financial contribution of the Community shall be
granted to Merial SAS in accordance with contractual
terms and conditions.

(10)

The measures provided for in this Decision are in
accordance with the opinion of the Standing Veterinary
Committee,

HAS ADOPTED THIS DECISION:

Article 1

1.
The Community shall grant financial assistance to France
for the stocking of antigens for the production of foot-and-
mouth disease vaccines.

(6) OJ L 160, 26.6.1999, p. 103.

L 13/26

EN

Official Journal of the European Communities

16.1.2002

The ‘Agence Française de Sécurité Sanitaire des Aliments
2.
(ASSA)’ at Lyon in France shall hold the stock of antigens to
which paragraph 1 relates.

3.
The Community's financial assistance shall be up to a
maximum of EUR 30 000 for the period 1 January to 31
December 2002.

Article 2

The Community shall grant financial assistance to Italy
1.
for the stocking of antigens for the production of foot-and-
mouth disease vaccines.

2.
The ‘Istituto Zooprofilattico Sperimentale Di Brescia’ in
Italy shall hold the stock of antigens to which paragraph 1
relates.

3.
The Community's financial assistance shall be up to a
maximum of EUR 30 000 for the period 1 January to 31
December 2002.

— insurance arrangements (fire, accidents);

(b) financial information (completion of table as shown in the

Annex).

Article 4

1.
The Community shall grant financial assistance to Merial
SAS, Lyon, France, for the stocking of antigens for the produc-
tion of foot-and-mouth disease vaccines.

2. Merial SAS, Lyon, shall hold the stock of antigens to
which paragraph 1 relates at the premises of Merial SAS in
Lyon, France, (two containers) and at the premises of Pirbright,
United Kingdom, (four containers).

The Community's financial assistance shall be up to a
3.
maximum of EUR 48 000 for the period 1 January to 31
December 2002.

Article 5

Article 3

To meet the objectives of Article 4, the Commission shall

1.
conclude a contract with Merial SAS without delay.

The Community's

1.
financial assistance referred to in
Article 1(3) and Article 2(3) shall be paid following the presen-
tation by the Member State concerned of supporting docu-
ments which demonstrate the effective completion of the tasks.

2.
The supporting documents referred to in paragraph 1
must be presented to the Commission before 1 March 2003
and they shall

include:

(a) technical

information on:

— the amount and type of antigen stored (storage records),
— storage equipment used (type, number and capacity of

tanks),

— security systems in place (temperature control, anti-

theft measures),

The Director-General of

2.
for
Health and Consumer Protection shall be authorised to sign the
contract on behalf of the European Commission.

the Directorate-General

This Decision is addressed to the Member States.

Article 6

Done at Brussels, 8 January 2002.

For the Commission

David BYRNE

Member of the Commission

16.1.2002

EN

Official Journal of the European Communities

L 13/27

ANNEX